Age-dependent prevalence of antibodies cross-reactive to the influenza A(H3N2) variant virus in sera collected in Norway in 2011
- PMID: 22607964
Age-dependent prevalence of antibodies cross-reactive to the influenza A(H3N2) variant virus in sera collected in Norway in 2011
Abstract
Antibody cross-reactivity to the influenza A(H3N2) variant virus recently reported in the United States, was investigated in Norwegian sera. Seroprevalence was 40% overall, and 71% in people born between 1977 and 1993. The most susceptible age groups were children and people aged around 50 years. The high immunity in young adults is likely to be due to strong priming infection with similar viruses in the 1990s. More research is needed to explain the poor immunity in 45–54 year-olds.
Similar articles
-
Cross-reactive and vaccine-induced antibody to an emerging swine-origin variant of influenza A virus subtype H3N2 (H3N2v).J Infect Dis. 2012 Dec 15;206(12):1852-61. doi: 10.1093/infdis/jis500. Epub 2012 Aug 7. J Infect Dis. 2012. PMID: 22872731
-
Antibodies cross-reactive to influenza A (H3N2) variant virus and impact of 2010-11 seasonal influenza vaccine on cross-reactive antibodies - United States.MMWR Morb Mortal Wkly Rep. 2012 Apr 13;61(14):237-41. MMWR Morb Mortal Wkly Rep. 2012. PMID: 22495226
-
A sentinel platform to evaluate influenza vaccine effectiveness and new variant circulation, Canada 2010-2011 season.Clin Infect Dis. 2012 Aug;55(3):332-42. doi: 10.1093/cid/cis431. Epub 2012 Apr 26. Clin Infect Dis. 2012. PMID: 22539661
-
Influenza vaccine 2008-2009.Med Lett Drugs Ther. 2008 Oct 6;50(1296):77-9. Med Lett Drugs Ther. 2008. PMID: 18833032 Review.
-
Correlates of vaccine protection from influenza and its complications.Hum Vaccin Immunother. 2012 Jan;8(1):34-44. doi: 10.4161/hv.8.1.18214. Epub 2012 Jan 1. Hum Vaccin Immunother. 2012. PMID: 22252001 Review.
Cited by
-
Antigenic drift and immunity gap explain reduction in protective responses against influenza A(H1N1)pdm09 and A(H3N2) viruses during the COVID-19 pandemic: a cross-sectional study of human sera collected in 2019, 2021, 2022, and 2023.Virol J. 2024 Mar 6;21(1):57. doi: 10.1186/s12985-024-02326-w. Virol J. 2024. PMID: 38448981 Free PMC article.
-
Age-seroprevalence curves for the multi-strain structure of influenza A virus.Nat Commun. 2021 Nov 18;12(1):6680. doi: 10.1038/s41467-021-26948-8. Nat Commun. 2021. PMID: 34795239 Free PMC article.
-
Baseline Levels of Influenza-Specific B Cells and T Cell Responses Modulate Human Immune Responses to Swine Variant Influenza A/H3N2 Vaccine.Vaccines (Basel). 2020 Mar 13;8(1):126. doi: 10.3390/vaccines8010126. Vaccines (Basel). 2020. PMID: 32183105 Free PMC article.
-
Heterologous Antibody Responses Conferred by A(H3N2) Variant and Seasonal Influenza Vaccination Against Newly Emerged 2016-2018 A(H3N2) Variant Viruses in Healthy Persons.Clin Infect Dis. 2020 Dec 15;71(12):3061-3070. doi: 10.1093/cid/ciz1203. Clin Infect Dis. 2020. PMID: 31858129 Free PMC article.
-
Safety and immunogenicity of unadjuvanted subvirion monovalent inactivated influenza H3N2 variant (H3N2v) vaccine in children and adolescents.Vaccine. 2019 Aug 23;37(36):5161-5170. doi: 10.1016/j.vaccine.2019.07.085. Epub 2019 Jul 30. Vaccine. 2019. PMID: 31375440 Free PMC article. Clinical Trial.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical

